(Q37244708)

19 August 2017

1 reference

title

Novel therapies in peripheral T-cell lymphomas (English)

1 reference

19 August 2017

Hilary M O'Leary

1

1 reference

PubMed ID

18706268

19 August 2017

Kerry J Savage

series ordinal

2

1 reference

19 August 2017

1 September 2008

1 reference

19 August 2017

Current Oncology Reports

1 reference

19 August 2017

10

1 reference

19 August 2017

5

1 reference

19 August 2017

404-411

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-008-0062-3

19 August 2017

0 references

cites work

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

1 reference

12 December 2020

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma

1 reference

12 December 2020

Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim

1 reference

12 December 2020

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

1 reference

12 December 2020

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma

1 reference

12 December 2020

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

12 December 2020

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)

1 reference

12 December 2020

Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.

1 reference

12 December 2020

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

12 December 2020

Towards understanding the peripheral T-cell lymphomas

1 reference

12 December 2020

DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma

1 reference

12 December 2020

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Pralatrexate: an emerging new agent with activity in T-cell lymphomas

1 reference

12 December 2020

Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

1 reference

12 December 2020

Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells

1 reference

12 December 2020

New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models

1 reference

12 December 2020

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

1 reference

12 December 2020

A denileukin diftitox (Ontak) associated retinopathy?

1 reference

12 December 2020

Peripheral T-cell lymphomas

1 reference

12 December 2020

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

1 reference

12 December 2020

Treatment of refractory T-cell malignancies using gemcitabine

1 reference

12 December 2020

Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study

1 reference

12 December 2020

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

1 reference

12 December 2020

The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma

1 reference

12 December 2020

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

1 reference

12 December 2020

Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines

1 reference

12 December 2020

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

1 reference

12 December 2020

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

1 reference

12 December 2020

Anthracycline resistance: the problem and its current definition

1 reference

12 December 2020

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice

1 reference

12 December 2020

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

1 reference

12 December 2020

Expression of CD52 in peripheral T-cell lymphoma

1 reference

12 December 2020

Synergistic interaction between cisplatin and gemcitabine in vitro.

1 reference

12 December 2020

Interaction between cisplatin and gemcitabine in vitro and in vivo.

1 reference

12 December 2020

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.

1 reference

12 December 2020

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

1 reference

12 December 2020

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

1 reference

12 December 2020

Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience

1 reference

12 December 2020

Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

1 reference

12 December 2020

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

1 reference

12 December 2020

New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.

1 reference

12 December 2020

Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score

1 reference

12 December 2020

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

1 reference

12 December 2020

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

1 reference

12 December 2020

10.1007/S11912-008-0062-3

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18706268